No Detail Found!

Evaluation of Cervical Cancer Screening Tools; INNO-LiPA® HPV Genotyping Extra-II Assay versus E7/E6 oncoproteins, How is reliable and practical?

Author(s)
REZA BAHRAMABADI Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
MOHAMMAD KAZEMI ARABABADI Research Institute of Basic Medical Sciences, and Department of Laboratory Sciences, Faculty of Paramedicine, Rafsanjan University of Medical Sciences,Rafsanjan,Iran
MARYAM IRANPOUR Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
ELHAM MOHEBBI Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran; Tehran University of Medical Sciences, Tehran, Iran.
ZAHRA HONARVAR Medical Sciences,Kerman 7616913555, Iran. E-mail Address:,Iran.; Department of Obstetrics and Gynecology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
MARYAM FEKRI SOOFI ABADI Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
SAHAR AMIRPOUR ROSTAMI Institute of Neuropharmacology, Kerman University of Medical Sciences,Kerman,Iran
MOHAMMAD SALAJEGHEH Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
FARDIN KHAJEPOUR Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
FATEMEH HASHEMI Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
SARA RASHIDI NEJAD Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
SHAHRIAR DABIRI Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences,Kerman,Iran
Abstract
Background: High-Risk Human papillomavirus (HR-HPV) has been well established as the cervical cancer (CC) risk factor. In recent years, various diagnostic methods of human papillomaviruses (HPV) have been developed to promote sensitivity and specificity of CC screening which leads to a low mortality rate. This study aimed to compare diagnostic test metrics of two HPV diagnostic techniques, including Western blot and INNO-LiPA HPV Genotyping Extra II assay methods in asymptomatic or subclinical patients, among the South-Eastern Iranian women. Methods: 323 women were referred to the Pathology and Stem Cell Research Center, from February 2018 to January 2020. HPV-DNA with the INNO-LiPA HPV Genotyping Extra-II Assay kit and the western blot assays for HPV E7 and E6 assessment were employed. Results: Overall, 163 (50.4%) samples were dysplastic pap smear, the specificity of the HPV DNA test by INNOLiPA HPV Genotyping Extra-II Assay test was significantly higher than the E7/E6 oncoproteins finding (67.3 vs. 49.9%), and the sensitivity was lower (96.6 vs. 74.8%), respectively. Conclusions: HR-HPV E7/E6 oncoproteins expression was evaluated as a possible novel biomarker for CC screening in pap smear as the preliminary test with satisfactory diagnostic values for HR-HPV types 16 and 18. The corresponding diagnostic values may be further improved by combining HPV DNA tests with the INNO-LiPA HPV Genotyping Extra-II test. Also, they may prove helpful for HR-HPV infection diagnosis in cases that the patients are asymptomatic or subclinical.
Publication Details
Page(s) 1276-1281
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 15, Issue: 5, Year: 2021

Request the full text from PASTIC

Keywords
Cervical Cancer, Oncogene Proteins, Diagnostic Screening Programs, Human Papillomavirus (HPV)
0

Citations

0

Downloads

75

Views